



Introduction

What is HTA?

Health Technology Assessment (HTA) bodies evaluate the clinical and/or economic impact of healthcare technologies to inform reimbursement policies

HTA expansion

As global healthcare expenditure grows, many countries are instituting or expanding the roles of HTA to achieve more affordable and equitable healthcare

Brazil and Argentina HTA



- The National Committee for Health Technology Incorporation (CONITEC) is the national HTA in Brazil established in 2011



- Plans to establish an official national HTA agency (Agency for Evaluation of Health Technologies; AGNET) have not yet been implemented
- However, the Institute for Clinical Effectiveness and Health Policy (IECS, established in 2003) issues HTA reports utilised by the interim national HTA agency (National Health Technology Assessment Commission; CONETEC)

Aims


This research evaluates HTA reports by CONITEC & IECS

Methodology

CONITEC and IECS HTA reports were identified from <http://conitec.gov.br/> and www.iecs.org.ar (01/01/2018-31/12/2020) and key information extracted

Brazil (CONITEC)


CONITEC HTA reports, per year



184 CONITEC HTA reports were identified

- 70 in 2018,
- 57 in 2019,
- 56 in 2020


CONITEC HTA outcomes, 2018-2020



- 47% of drug HTA report outcomes were to include in the Sistema Único de Saúde (SUS, Brazil's publicly funded national healthcare system),
- 39% were not to be incorporated into the SUS,
- 9% were to expand the use of a medicine,
- 4% to not expand the use, and
- 4% were excluded/removed

Argentina (IECS)

IECS reports, per year




294 IECS reports were identified

- 125 in 2018,
- 70 in 2019,
- 99 in 2020

67% were HTA reports & 33% individual patient requests

IECS HTA reports, by indication, 2018-2020



The most common indications assessed as part of HTA reports were:

- oncology (17%)
- Infectious diseases (14%)
- neurology (10%).

Conclusions

CONITEC and IECS represent HTA bodies in two of the biggest Latin American pharmaceutical markets, both issuing an average of over 80 reports per year.



CONITEC have been particularly impactful in Brazil, not recommending reimbursement of almost 40% of technologies assessed



The implementation of the new HTA body AGNET in Argentina and its impact on national access for medicines will be an important focus for future research